Recent Developments in Gene Targeted and Immunotherapies of Parkinson's Disease

Presented by

Roy N. Alcalay, MD
Joseph Quinn, MD
Carlos Singer, MD

Course Description

The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression.

The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD.  Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.

This webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.

Target Audience

This course is intended for neurologists interested or specializing in Movement Disorders.

Learning Objectives
  1. Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD
  2. Explain the current state of development of clinical trials of both therapies
  3. Recognize the use of biomarkers to monitor target engagement and effect on progression of PD
  4. Identify future directions of these novel therapeutic modalities

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice